111 related articles for article (PubMed ID: 24983389)
1. Cost-effectiveness of antiretroviral therapy expansion strategies in Vietnam.
Tran DA; Wilson DP; Shakeshaft A; Ngo AD; Reyes J; Doran C; Zhang L
AIDS Patient Care STDS; 2014 Jul; 28(7):365-71. PubMed ID: 24983389
[TBL] [Abstract][Full Text] [Related]
2. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.
Eaton JW; Menzies NA; Stover J; Cambiano V; Chindelevitch L; Cori A; Hontelez JA; Humair S; Kerr CC; Klein DJ; Mishra S; Mitchell KM; Nichols BE; Vickerman P; Bakker R; Bärnighausen T; Bershteyn A; Bloom DE; Boily MC; Chang ST; Cohen T; Dodd PJ; Fraser C; Gopalappa C; Lundgren J; Martin NK; Mikkelsen E; Mountain E; Pham QD; Pickles M; Phillips A; Platt L; Pretorius C; Prudden HJ; Salomon JA; van de Vijver DA; de Vlas SJ; Wagner BG; White RG; Wilson DP; Zhang L; Blandford J; Meyer-Rath G; Remme M; Revill P; Sangrujee N; Terris-Prestholt F; Doherty M; Shaffer N; Easterbrook PJ; Hirnschall G; Hallett TB
Lancet Glob Health; 2014 Jan; 2(1):e23-34. PubMed ID: 25104632
[TBL] [Abstract][Full Text] [Related]
3. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.
Badri M; Cleary S; Maartens G; Pitt J; Bekker LG; Orrell C; Wood R
Antivir Ther; 2006; 11(1):63-72. PubMed ID: 16518961
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of population-level expansion of highly active antiretroviral treatment for HIV in British Columbia, Canada: a modelling study.
Nosyk B; Min JE; Lima VD; Hogg RS; Montaner JS;
Lancet HIV; 2015 Sep; 2(9):e393-400. PubMed ID: 26423553
[TBL] [Abstract][Full Text] [Related]
5. Optimal frequency of CD4 cell count and HIV RNA monitoring prior to initiation of antiretroviral therapy in HIV-infected patients.
Kimmel AD; Goldie SJ; Walensky RP; Losina E; Weinstein MC; Paltiel AD; Zhang H; Freedberg KA;
Antivir Ther; 2005; 10(1):41-52. PubMed ID: 15751762
[TBL] [Abstract][Full Text] [Related]
6. Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy.
Freedberg KA; Kumarasamy N; Losina E; Cecelia AJ; Scott CA; Divi N; Flanigan TP; Lu Z; Weinstein MC; Wang B; Ganesh AK; Bender MA; Mayer KH; Walensky RP
AIDS; 2007 Jul; 21 Suppl 4(Suppl 4):S117-28. PubMed ID: 17620747
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of community-based strategies to strengthen the continuum of HIV care in rural South Africa: a health economic modelling analysis.
Smith JA; Sharma M; Levin C; Baeten JM; van Rooyen H; Celum C; Hallett TB; Barnabas RV
Lancet HIV; 2015 Apr; 2(4):e159-68. PubMed ID: 25844394
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States.
Brogan AJ; Talbird SE; Cohen C
Value Health; 2011; 14(5):657-64. PubMed ID: 21839403
[TBL] [Abstract][Full Text] [Related]
9. Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis.
Boyer S; March L; Kouanfack C; Laborde-Balen G; Marino P; Aghokeng AF; Mpoudi-Ngole E; Koulla-Shiro S; Delaporte E; Carrieri MP; Spire B; Laurent C; Moatti JP;
Lancet Infect Dis; 2013 Jul; 13(7):577-86. PubMed ID: 23602084
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of optimized background therapy plus maraviroc for previously treated patients with R5 HIV-1 infection from the perspective of the Spanish health care system.
Moreno S; González J; Lekander I; Martí B; Oyagüez I; Sánchez-de la Rosa R; Casado MA
Clin Ther; 2010 Dec; 32(13):2232-45. PubMed ID: 21316539
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in Côte d'Ivoire: A model-based analysis.
Ouattara EN; MacLean RL; Danel C; Borre ED; Gabillard D; Huang M; Moh R; Paltiel AD; Eholié SP; Walensky RP; Anglaret X; Freedberg KA
PLoS One; 2019; 14(6):e0219068. PubMed ID: 31247009
[TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa.
Alistar SS; Grant PM; Bendavid E
BMC Med; 2014 Mar; 12():46. PubMed ID: 24629217
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV.
Corzillius M; Mühlberger N; Sroczynski G; Jaeger H; Wasem J; Siebert U
Antivir Ther; 2004 Feb; 9(1):27-36. PubMed ID: 15040534
[TBL] [Abstract][Full Text] [Related]
14. Initiation of antiretroviral therapy based on the 2015 WHO guidelines.
Kuznik A; Iliyasu G; Habib AG; Musa BM; Kambugu A; Lamorde M
AIDS; 2016 Nov; 30(18):2865-2873. PubMed ID: 27662547
[TBL] [Abstract][Full Text] [Related]
15. Economic and epidemiologic impact of guidelines for early ART initiation irrespective of CD4 count in Spain.
Kasaie P; Radford M; Kapoor S; Jung Y; Hernandez Novoa B; Dowdy D; Shah M
PLoS One; 2018; 13(11):e0206755. PubMed ID: 30395635
[TBL] [Abstract][Full Text] [Related]
16. The Cost-Effectiveness of Human Immunodeficiency Virus Testing and Treatment Engagement Initiatives in British Columbia, Canada: 2011-2013.
Nosyk B; Min JE; Krebs E; Zang X; Compton M; Gustafson R; Barrios R; Montaner JSG;
Clin Infect Dis; 2018 Feb; 66(5):765-777. PubMed ID: 29028964
[TBL] [Abstract][Full Text] [Related]
17. Determinants of virological failure after 1 year's antiretroviral therapy in Vietnamese people with HIV: findings from a retrospective cohort of 13 outpatient clinics in six provinces.
Tran DA; Wilson DP; Shakeshaft A; Ngo AD; Doran C; Zhang L
Sex Transm Infect; 2014 Nov; 90(7):538-44. PubMed ID: 24619575
[TBL] [Abstract][Full Text] [Related]
18. Economics of switching to second-line antiretroviral therapy with lopinavir/ritonavir in Africa: estimates based on DART trial results and costs for Uganda and Kenya.
Simpson KN; Baran RW; Kirbach SE; Dietz B
Value Health; 2011 Dec; 14(8):1048-54. PubMed ID: 22152173
[TBL] [Abstract][Full Text] [Related]
19. Does directly administered antiretroviral therapy represent good value for money in sub-Saharan Africa? A cost-utility and value of information analysis.
Uthman RT; Sutton AJ; Jackson LJ; Uthman OA
PLoS One; 2018; 13(1):e0191465. PubMed ID: 29360841
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of alternative strategies for initiating and monitoring highly active antiretroviral therapy in the developing world.
Vijayaraghavan A; Efrusy MB; Mazonson PD; Ebrahim O; Sanne IM; Santas CC
J Acquir Immune Defic Syndr; 2007 Sep; 46(1):91-100. PubMed ID: 17621241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
